Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 1,635 Shares of Stock

Key Points

• Insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics at an average price of $10.17, resulting in a total transaction of approximately $16,627.95, decreasing his ownership by 23.96%.
• The company's stock price fluctuated, reaching $11.27 per share, with a market capitalization of $526.31 million and a 12-month trading range between $2.23 and $11.29.
• Analysts maintain a consensus rating of "Moderate Buy" for 4D Molecular Therapeutics, with an average target price of $30.40, despite recent earnings missing expectations and negative earnings per share of ($0.98).

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $10.17, for a total transaction of $16,627.95. Following the sale, the insider owned 5,188 shares of the company's stock, valued at $52,761.96. This represents a 23.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT traded up $1.43 during trading on Monday, hitting $11.27. 932,525 shares of the company were exchanged, compared to its average volume of 765,014. The stock has a market capitalization of $526.31 million, a P/E ratio of -3.19 and a beta of 2.93. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $11.29. The firm's 50 day moving average price is $7.68 and its 200-day moving average price is $5.22.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. As a group, equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently bought and sold shares of FDMT. BVF Inc. IL increased its stake in 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after buying an additional 1,890,647 shares during the period. Federated Hermes Inc. increased its stake in 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock valued at $4,038,000 after buying an additional 1,246,419 shares during the period. Acadian Asset Management LLC increased its stake in 4D Molecular Therapeutics by 1,103.4% in the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock valued at $1,290,000 after buying an additional 367,317 shares during the period. Millennium Management LLC increased its stake in 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after buying an additional 213,264 shares during the period. Finally, Raymond James Financial Inc. grew its stake in shares of 4D Molecular Therapeutics by 54.7% during the 2nd quarter. Raymond James Financial Inc. now owns 455,470 shares of the company's stock worth $1,690,000 after purchasing an additional 161,091 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Roth Capital reduced their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.